Cargando…
Biodistribution and pharmacokinetics of(111)In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies
The biodistribution and pharmacokinetics of(111)In-DTPA-labelled pegylated liposomes in tumour-bearing nude mice was studied to examine possible applications of pegylated liposome-targeted anti-cancer therapies. Nude mice received an intravenous injection of 100 μl of(111)In-DTPA-labelled pegylated...
Autores principales: | Harrington, K J, Rowlinson-Busza, G, Syrigos, K N, Uster, P S, Abra, R M, Stewart, J S W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363473/ https://www.ncbi.nlm.nih.gov/pubmed/10901376 http://dx.doi.org/10.1054/bjoc.1999.1232 |
Ejemplares similares
-
Influence of tumour size on uptake of(111)In-DTPA-labelled pegylated liposomes in a human tumour xenograft model
por: Harrington, K J, et al.
Publicado: (2000) -
Targeted radiosensitisation by pegylated liposome-encapsulated 3′, 5′-O-dipalmitoyl 5-iodo-2′-deoxyuridine in a head and neck cancer xenograft model
por: Harrington, K J, et al.
Publicado: (2004) -
The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
por: Dadpour, Saba, et al.
Publicado: (2022) -
Correlation between radioactivity and chemotherapeutics of the (111)In-VNB-liposome in pharmacokinetics and biodistribution in rats
por: Lee, Wen-Chuan, et al.
Publicado: (2012) -
Pharmacokinetics, Biodistribution, and Biosafety of PEGylated Gold Nanoparticles In Vivo
por: Kozics, Katarina, et al.
Publicado: (2021)